Overview of Dr. Furman
Dr. Richard Furman is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, and New York-Presbyterian Hospital. He received his medical degree from Icahn School of Medicine at Mount Sinai and has been in practice 24 years. Dr. Furman accepts several types of health insurance, listed below. He is one of 368 doctors at New York-Presbyterian Hospital and one of 368 doctors at New York-Presbyterian Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
520 East 70th Street
Starr Pavilion, 3rd Floor
New York, NY 10021- Is this information wrong?
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1996 - 1999
University of Pennsylvania Health SystemResidency, Internal Medicine, 1993 - 1996
Icahn School of Medicine at Mount SinaiClass of 1993
Certifications & Licensure
FL State Medical License 2022 - Present
NY State Medical License 1996 - 2026
NJ State Medical License 2022 - 2025
PA State Medical License 1994 - 1996
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies Start of enrollment: 2007 Jun 01
- A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) Start of enrollment: 2009 Sep 01
- Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL Start of enrollment: 2012 Mar 30
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsHyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.Stephen Jun Fei Chong, Fen Zhu, Olga Dashevsky, Rin Mizuno, Jolin Xh Lai, Liam Hackett, Christine E Ryan, Mary C Collins, J Bryan Iorgulescu, Romain Guièze, Johany Pen...> ;The Journal of Clinical Investigation. 2023 Nov 15
- 2 citationsNine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma.Samuel Yamshon, Gui Zhen Chen, Caitlin Gribbin, Paul Christos, Bijal Shah, Stephen J Schuster, Sonali M Smith, Jakub Svoboda, Richard R Furman, John P Leonard, Peter M...> ;Blood Advances. 2023 Nov 14
- Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenström Macroglobulinemia.Mark Bustoros, Caitlin Gribbin, Jorge J Castillo, Richard Furman> ;Hematology/oncology Clinics of North America. 2023 Aug 1
- Join now to see all
Journal Articles
- Targeting CD38 with Daratumumab Is Lethal to Waldenström Macroglobulinaemia CellsRichard Furman, Stephen M Ansell, Sikander Ailawadhi, Thomas E Witzig, Vivek Roy, Taimur Sher, Liuyan Jiang, British Journal of Haematology
- Five-Year Follow-up of Lenalidomide plus Rituximab as Initial Treatment for Mantle Cell LymphomaJia Ruan, Jakub Svoboda, John P Leonard, Sonali M Smith, Morton Coleman, Richard R Furman, Blood
- Real World Outcomes and Management Strategies for Venetoclax-Treated Chronic Lymphocytic Leukemia Patients in the United StatesArun K Singavi, Andrew Zelenetz, Nicole Lamanna, Bruce D Cheson, Richard R Furman, Jakub Svoboda, Stephen J Schuster, John N Allan, Chaitra S Ujjani, Haematologica
- Join now to see all
Abstracts/Posters
- CD79b Expression in Richter's TransformationRichard R. Furman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- The Dual PI3K-_/_ Inhibitor Duvelisib in Combination with the Bcl-2 Inhibitor Venetoclax Shows Promising Responses in Richter Syndrome-PDX ModelsRichard R. Furman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...Richard R. Furman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- How I Think, How I Treat - BTK Inhibitors as a Clinical Strategy in CLL, MCL, and Beyond: Therapeutic Selection, Sequencing, and Next Steps61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- NOTCH1 Stabilization By PEST Mutations Enhances IgM-Mediated Activity in Chronic Lymphocytic Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
42-Month Follow-up Data of Acalabrutinib Monotherapy in R/R CLLDecember 9th, 2019
MMP ArchiveAugust 7th, 2019
Tracking the Epigenetic Evolution of a Cancer, Cell by CellMay 16th, 2019- Join now to see all
Professional Memberships
- Member
- Member
- Member
Hospital Affiliations
New York-Presbyterian HospitalNew York, New York- New York-Presbyterian HospitalNew York, New York
- New York-Presbyterian HospitalNew York, New York
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Alabama PPO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPOGreat West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
